Imaging plays a major and growing role in non-invasively assessing cancer biology both pre-clinically and in clinical translational studies. Imaging is now being used to personalize therapies in clinical practice. In early and advanced clinical trials of cancer therapeutics, imaging can provide key information on the mechanisms of action of the treatment, including whether targets are present, whether the target is "hit" by the therapy, whether the cancer is responding and if tumor progression has occurred. Elements of such measurements are an important part of many studies involving cancer therapy conducted at the Sidney Kimmell Cancer Center at JHU. Qualitative imaging is now being complemented by sophisticated quantitative approaches. To assure access to advanced imaging technologies including quantitative PET, MRl, and CT the Imaging Response Assessment Laboratory (IRAT) has been established within the SKCC. The IRAT was first established as a competitive NCI supplement to the CCSG, and is now being transitioned to a Core service available to cancer center investigators. Services of the IFWVT available to SKCC investigators include: a) Consultation and guidance on the proper choice, design and use of imaging studies in clinical trials, b) Expert reviews of clinical protocols to assure that the imaging protocol and analysis plans are appropriate for the chosen task, c) State of the art prompt and accurate assessment of tumor response using standardized anatomic and metabolic response criteria, including RECIST 1.1, PERCIST 1.0, d) Image archival, anonymization, and data import / export, e) Developing documents, protocols and forms to assist in studies performed at one or multiple sites, g) Regulatory guidance on radiation exposure and molecular imaging agents, and h) Improving collaborations among cancer center investigators and imaging specialists in quantitative imaging. Future plans include assuring computing and software platforms are updated to continue to provide robust quantitative analyses of single and multimodal imaging studies of cancer treatment response with current and emerging imaging tools. IRAT input into study design and analysis is expected to lead to more appropriate, accurate and reproducible imaging in cancer therapy studies performed at JHU and in collaboration with other institutions. Appropriate quantitative imaging should benefit clinical cancer therapy trials of all phases and should accelerate translational cancer research. Lay: For cancers to be treated effectively and for new treatments to be tested and evaluated, precise non-invasive quantitative imaging of the location, size and biological characteristics of the cancers is essential. The IFJAT core uses PET, MRl, CT and other tools to evaluate tumors, determine if they are likely to respond to treatment and quantifies quickly and accurately whether the tumors are suitable for a given treatment, are responding to treatment or are failing to respond

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-50
Application #
8559752
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
50
Fiscal Year
2013
Total Cost
$221,700
Indirect Cost
$84,848
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Hurley, Paula J; Sundi, Debasish; Shinder, Brian et al. (2016) Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer. Clin Cancer Res 22:448-58
Roberts, Nicholas J; Norris, Alexis L; Petersen, Gloria M et al. (2016) Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discov 6:166-75
Chen, Zhihang; Penet, Marie-France; Krishnamachary, Balaji et al. (2016) PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer. Biomaterials 80:57-67
Castanares, Mark A; Copeland, Ben T; Chowdhury, Wasim H et al. (2016) Characterization of a novel metastatic prostate cancer cell line of LNCaP origin. Prostate 76:215-25
Anders, Nicole M; Wanjiku, Teresia M; He, Ping et al. (2016) A robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of 5-azacytidine. Biomed Chromatogr 30:494-6
Morgan, Michael T; Haj-Yahya, Mahmood; Ringel, Alison E et al. (2016) Structural basis for histone H2B deubiquitination by the SAGA DUB module. Science 351:725-8
Mao, Kai; Liu, Jieqiong; Sun, Jian et al. (2016) Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma. J Gastroenterol Hepatol 31:417-26
Morais, Carlos L; Guedes, Liana B; Hicks, Jessica et al. (2016) ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma. Hum Pathol 55:117-25
Wang, Zhijun; Hansis, Eberhard; Chen, Rongxin et al. (2016) Automatic bone removal for 3D TACE planning with C-arm CBCT: Evaluation of technical feasibility. Minim Invasive Ther Allied Technol 25:162-70
Vrooman, Lynda M; Kirov, Ivan I; Dreyer, ZoAnn E et al. (2016) Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia. Pediatr Blood Cancer 63:228-33

Showing the most recent 10 out of 1943 publications